The intrinsic role and mechanism of tumor expressed-CD38 on lung adenocarcinoma progression
Abstract It has been recently reported that CD38 expressed on tumor cells of multiple murine and human origins could be upregulated in response to PD-L1 antibody therapy, which led to dysfunction of tumor-infiltrating CD8+ T immune cells due to increasing the production of adenosine. However, the ro...
| Published in: | Cell Death and Disease |
|---|---|
| Main Authors: | Long Gao, Yuan Liu, Xiaohong Du, Sai Ma, Minmin Ge, Haijun Tang, Chenfeng Han, Xin Zhao, Yanbin Liu, Yun Shao, Zhao Wu, Lianjun Zhang, Fang Meng, F. Xiao-Feng Qin |
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-07-01
|
| Online Access: | https://doi.org/10.1038/s41419-021-03968-2 |
Similar Items
Identification of cancer cell-intrinsic biomarkers associated with tumor progression and characterization of SFTA3 as a tumor suppressor in lung adenocarcinomas
by: Yu Zhao, et al.
Published: (2025-01-01)
by: Yu Zhao, et al.
Published: (2025-01-01)
Cystine deprivation triggers CD36-mediated ferroptosis and dysfunction of tumor infiltrating CD8+ T cells
by: Chenfeng Han, et al.
Published: (2024-02-01)
by: Chenfeng Han, et al.
Published: (2024-02-01)
Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38
by: Song Li, et al.
Published: (2024-06-01)
by: Song Li, et al.
Published: (2024-06-01)
CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer
by: Wei Wang, et al.
Published: (2025-07-01)
by: Wei Wang, et al.
Published: (2025-07-01)
MYST2 histone acetyltransferase promotes lung adenocarcinoma progression by regulating the p38 MAPK signaling pathway
by: Zhiang Huang, et al.
Published: (2025-01-01)
by: Zhiang Huang, et al.
Published: (2025-01-01)
Intratumoral CD38+CD19+B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinomaResearch in context
by: Heng Zhu, et al.
Published: (2024-05-01)
by: Heng Zhu, et al.
Published: (2024-05-01)
Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity
by: Lifeng Li, et al.
Published: (2019-06-01)
by: Lifeng Li, et al.
Published: (2019-06-01)
CD38 in Neurodegeneration and Neuroinflammation
by: Serge Guerreiro, et al.
Published: (2020-02-01)
by: Serge Guerreiro, et al.
Published: (2020-02-01)
Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
by: Torben Plesner, et al.
Published: (2020-02-01)
by: Torben Plesner, et al.
Published: (2020-02-01)
The recruitment of CD8+ T cells through YBX1 stabilization abrogates tumor intrinsic oncogenic role of MIR155HG in lung adenocarcinoma
by: Rutao Li, et al.
Published: (2024-07-01)
by: Rutao Li, et al.
Published: (2024-07-01)
BANF1 as a potential prognostic biomarker associated with tumor-intrinsic programs and a complex immune landscape in lung adenocarcinoma
by: Meihan Liu, et al.
Published: (2026-04-01)
by: Meihan Liu, et al.
Published: (2026-04-01)
Intrinsic Immunogenic Tumor Cell Death Subtypes Delineate Prognosis and Responsiveness to Immunotherapy in Lung Adenocarcinoma
by: Xiaotian He, et al.
Published: (2023-06-01)
by: Xiaotian He, et al.
Published: (2023-06-01)
Association of FANCD2, TFPI, and CD33 genes with prognosis of lung adenocarcinoma: a bioinformatics study
by: Guixin He, et al.
Published: (2025-10-01)
by: Guixin He, et al.
Published: (2025-10-01)
The predictive value of 18F-FDG PET/CT habitat radiomics combined model in evaluating EGFR gene mutations in lung adenocarcinoma
by: Ruihe Lai, et al.
Published: (2026-06-01)
by: Ruihe Lai, et al.
Published: (2026-06-01)
CD38 connects the heart and brain
by: Yijing Tao, et al.
Published: (2025-09-01)
by: Yijing Tao, et al.
Published: (2025-09-01)
CD38 as theranostic target in oncology
by: Valentina Bocuzzi, et al.
Published: (2024-11-01)
by: Valentina Bocuzzi, et al.
Published: (2024-11-01)
Targeting CD38 for acute leukemia
by: Xushu Zhong, et al.
Published: (2022-10-01)
by: Xushu Zhong, et al.
Published: (2022-10-01)
ZDHHC9-mediated CD38 palmitoylation stabilizes CD38 expression and promotes pancreatic cancer growth
by: Hui Guo, et al.
Published: (2025-03-01)
by: Hui Guo, et al.
Published: (2025-03-01)
LncRNA MANCR positively affects the malignant progression of lung adenocarcinoma
by: Chang Liu, et al.
Published: (2021-08-01)
by: Chang Liu, et al.
Published: (2021-08-01)
CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells
by: Chan Liao, et al.
Published: (2023-09-01)
by: Chan Liao, et al.
Published: (2023-09-01)
HOXA9 and CD163 potentiate pancreatic ductal adenocarcinoma progression
by: Aiat Shaban Hemida, et al.
Published: (2024-10-01)
by: Aiat Shaban Hemida, et al.
Published: (2024-10-01)
Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
by: Beatrice Anna Zannetti, et al.
Published: (2020-12-01)
by: Beatrice Anna Zannetti, et al.
Published: (2020-12-01)
Chromosome X Open Reading Frame 38 (CXorf38) Is a Tumor Suppressor and Potential Prognostic Biomarker in Lung Adenocarcinoma: The First Characterization
by: Rui Yan, et al.
Published: (2025-06-01)
by: Rui Yan, et al.
Published: (2025-06-01)
Ikaros is heterogeneously expressed in lung adenocarcinoma and is involved in its progression
by: Wei Zhao, et al.
Published: (2020-08-01)
by: Wei Zhao, et al.
Published: (2020-08-01)
High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells
by: Long Chen, et al.
Published: (2022-02-01)
by: Long Chen, et al.
Published: (2022-02-01)
Targeting CD38 in Antibody-Mediated Rejection
by: Katharina A. Mayer, et al.
Published: (2025-05-01)
by: Katharina A. Mayer, et al.
Published: (2025-05-01)
Correction to: CD38 as theranostic target in oncology
by: Valentina Bocuzzi, et al.
Published: (2024-12-01)
by: Valentina Bocuzzi, et al.
Published: (2024-12-01)
Evaluation of diagnostic potential of CD38 in rickets
by: Yongjie Xia, et al.
Published: (2024-02-01)
by: Yongjie Xia, et al.
Published: (2024-02-01)
Roles of CD38 in the Immune Response to Infection
by: Estibaliz Glaría, et al.
Published: (2020-01-01)
by: Estibaliz Glaría, et al.
Published: (2020-01-01)
CD38: T Cell Immuno-Metabolic Modulator
by: Anwesha Kar, et al.
Published: (2020-07-01)
by: Anwesha Kar, et al.
Published: (2020-07-01)
CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity
by: Zayda L. Piedra-Quintero, et al.
Published: (2020-11-01)
by: Zayda L. Piedra-Quintero, et al.
Published: (2020-11-01)
Role of CD38 in anti-tumor immunity of small cell lung cancer
by: Hirokazu Taniguchi, et al.
Published: (2024-03-01)
by: Hirokazu Taniguchi, et al.
Published: (2024-03-01)
CD38, CD157, and RAGE as Molecular Determinants for Social Behavior
by: Haruhiro Higashida, et al.
Published: (2019-12-01)
by: Haruhiro Higashida, et al.
Published: (2019-12-01)
Effect of hyperthermia on intestinal microecology, immune function, and progression-free survival in patients with advanced unresectable lung adenocarcinoma
by: Jin Tian, et al.
Published: (2023-10-01)
by: Jin Tian, et al.
Published: (2023-10-01)
Correlation of CD19+CD24hiCD38hi B cells in coronary artery disease with severity of atherosclerosis
by: Yang Liu, et al.
Published: (2020-05-01)
by: Yang Liu, et al.
Published: (2020-05-01)
T-lymphoid differentiation potential measured in vitro is higher in CD34+CD38−/lo hematopoietic stem cells from umbilical cord blood than from bone marrow and is an intrinsic property of the cells
by: Magda De Smedt, et al.
Published: (2011-05-01)
by: Magda De Smedt, et al.
Published: (2011-05-01)
Phosphorescence of Carbon Dot: The Intrinsic Mechanism and Recent Progress
by: Kun Zuo, et al.
Published: (2023-09-01)
by: Kun Zuo, et al.
Published: (2023-09-01)
The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia.
by: Runxia Gu, et al.
Published: (2017-01-01)
by: Runxia Gu, et al.
Published: (2017-01-01)
Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
by: Maxime Fayon, et al.
Published: (2020-07-01)
by: Maxime Fayon, et al.
Published: (2020-07-01)
103 Quality improvement of anti-CD38-JAK/STAT CAR-T cells by suppressing CD38 expression and inhibition of tyrosine kinase
by: Sachiko Okamoto, et al.
Published: (2021-11-01)
by: Sachiko Okamoto, et al.
Published: (2021-11-01)
Similar Items
-
Identification of cancer cell-intrinsic biomarkers associated with tumor progression and characterization of SFTA3 as a tumor suppressor in lung adenocarcinomas
by: Yu Zhao, et al.
Published: (2025-01-01) -
Cystine deprivation triggers CD36-mediated ferroptosis and dysfunction of tumor infiltrating CD8+ T cells
by: Chenfeng Han, et al.
Published: (2024-02-01) -
Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38
by: Song Li, et al.
Published: (2024-06-01) -
CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer
by: Wei Wang, et al.
Published: (2025-07-01) -
MYST2 histone acetyltransferase promotes lung adenocarcinoma progression by regulating the p38 MAPK signaling pathway
by: Zhiang Huang, et al.
Published: (2025-01-01)
